Chicago, March 11, 2025 – Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-powered precision medicine, has announced the acquisition of Deep 6 AI, a cutting-edge clinical trial software company specializing in AI-driven patient recruitment and real-world evidence (RWE) generation. The acquisition is set to significantly enhance Tempus’ capabilities in clinical research and patient care, reinforcing its mission to accelerate the future of AI-driven healthcare.

Enhancing Clinical Trial Recruitment and Precision Medicine

Deep 6 AI is recognized for its innovative use of artificial intelligence to analyze both structured and unstructured electronic medical records (EMRs) across a vast network of healthcare institutions. The company’s platform is integrated into over 750 provider site locations, covering more than 30 million patients, making it a vital asset for identifying and recruiting patients for clinical trials.

By acquiring Deep 6 AI, Tempus is poised to expand its reach in precision medicine, integrating Deep 6’s capabilities into its own ecosystem to optimize clinical trial matching, real-world data analysis, and treatment decision-making.

A Strategic Step Toward AI-Powered Healthcare

“This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and TIME, which helps patients find potentially life-saving clinical trials,” said Eric Lefkofsky, Founder and CEO of Tempus.

The integration of Deep 6 AI’s infrastructure aligns seamlessly with Tempus’ strategy to leverage multimodal data and AI-powered solutions to improve clinical outcomes. The move will help de-risk clinical trials, accelerate recruitment, and enable more precise patient stratification, thereby reducing the time and cost associated with bringing new treatments to market.

Implications for Healthcare and Life Sciences

Faster and More Efficient Clinical Trials – AI-driven patient matching will reduce recruitment timelines and improve trial efficiency.
Optimized Precision Medicine – Physicians will gain enhanced decision-support tools powered by a more robust dataset.
✔Stronger AI-Driven Insights – The combined expertise of Tempus and Deep 6 AI will create a more comprehensive AI-powered research ecosystem, benefiting both life sciences companies and healthcare providers.

The Future of AI in Healthcare

With this acquisition, Tempus strengthens its position at the forefront of AI-driven healthcare, setting a new benchmark for data-driven patient care and clinical research. By expanding its network and technological capabilities, Tempus continues to redefine the intersection of AI, medicine, and real-world evidence.

About Tempus
Tempus is a technology company advancing precision medicine through AI-powered solutions in healthcare. With one of the world’s largest multimodal data libraries, Tempus enables physicians and researchers to deliver personalized patient care and optimize drug development.